Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
@prefix fhir: <http://hl7.org/fhir/> . @prefix owl: <http://www.w3.org/2002/07/owl#> . @prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> . @prefix xsd: <http://www.w3.org/2001/XMLSchema#> . # - resource ------------------------------------------------------------------- a fhir:Bundle ; fhir:nodeRole fhir:treeRoot ; fhir:id [ fhir:v "bundlepackageleaflet-en-2dca39e00c4bb300a2d0bc7e52b63f20"] ; # fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"^^xsd:anyURI ; fhir:link <http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi> ] ) ] ; # fhir:language [ fhir:v "en"] ; # fhir:identifier [ fhir:system [ fhir:v "http://ema.europa.eu/identifier"^^xsd:anyURI ] ; fhir:value [ fhir:v "None" ] ] ; # fhir:type [ fhir:v "document"] ; # fhir:timestamp [ fhir:v "2023-06-27T10:09:22Z"^^xsd:dateTime] ; # fhir:entry ( [ fhir:fullUrl [ fhir:v "Composition/composition-en-2dca39e00c4bb300a2d0bc7e52b63f20"^^xsd:anyURI ] ; ( fhir:resource <Composition/composition-en-2dca39e00c4bb300a2d0bc7e52b63f20> ) ] [ fhir:fullUrl [ fhir:v "MedicinalProductDefinition/mp2dca39e00c4bb300a2d0bc7e52b63f20"^^xsd:anyURI ] ; ( fhir:resource <MedicinalProductDefinition/mp2dca39e00c4bb300a2d0bc7e52b63f20> ) ] ) . # <Composition/composition-en-2dca39e00c4bb300a2d0bc7e52b63f20> a fhir:Composition ; fhir:id [ fhir:v "composition-en-2dca39e00c4bb300a2d0bc7e52b63f20"] ; # fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"^^xsd:anyURI ; fhir:link <http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi> ] ) ] ; # fhir:language [ fhir:v "en"] ; # fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\" xml:lang=\"en\" lang=\"en\"><a name=\"Composition_composition-en-2dca39e00c4bb300a2d0bc7e52b63f20\"> </a><p class=\"res-header-id\"><b>Generated Narrative: Composition composition-en-2dca39e00c4bb300a2d0bc7e52b63f20</b></p><a name=\"composition-en-2dca39e00c4bb300a2d0bc7e52b63f20\"> </a><a name=\"hccomposition-en-2dca39e00c4bb300a2d0bc7e52b63f20\"> </a><a name=\"composition-en-2dca39e00c4bb300a2d0bc7e52b63f20-en-US\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Language: en</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html\">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/00/156/002 – opaque white PCTFE/PVC-Al Blister pack (60 Tablets)</p><p><b>status</b>: Final</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}\">Package Leaflet</span></p><p><b>category</b>: <span title=\"Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}\">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href=\"Organization-mah-ema.html\">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - trizivir</p><h3>Attesters</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{http://hl7.org/fhir/composition-attestation-mode official}\">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>" ] ; # fhir:identifier ( [ fhir:system [ fhir:v "http://ema.europa.eu/identifier"^^xsd:anyURI ] ; fhir:value [ fhir:v "EU/1/00/156/002 – opaque white PCTFE/PVC-Al Blister pack (60 Tablets)" ] ] ) ; # fhir:status [ fhir:v "final"] ; # fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "Package Leaflet" ] ] ; # fhir:category ( [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"^^xsd:anyURI ] ; fhir:code [ fhir:v "R" ] ; fhir:display [ fhir:v "Raw" ] ] ) ] ) ; # fhir:subject ( [ fhir:reference [ fhir:v "MedicinalProductDefinition/mp2dca39e00c4bb300a2d0bc7e52b63f20" ] ] ) ; # fhir:date [ fhir:v "2022-02-16T13:28:17Z"^^xsd:dateTime] ; # fhir:author ( [ fhir:reference [ fhir:v "Organization/mah-ema" ] ] ) ; # fhir:title [ fhir:v "TEST PURPOSES ONLY - trizivir"] ; # fhir:attester ( [ fhir:mode [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/composition-attestation-mode"^^xsd:anyURI ] ; fhir:code [ fhir:v "official" ] ] ) ] ; fhir:time [ fhir:v "2022-02-16T13:28:17Z"^^xsd:dateTime ] ] ) ; # fhir:section ( [ fhir:title [ fhir:v "B. Package Leaflet" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "B. Package Leaflet" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">unavailable</div>" ] ; fhir:emptyReason [ ( fhir:coding [ fhir:system [ fhir:v "http://terminology.hl7.org/CodeSystem/list-empty-reason"^^xsd:anyURI ] ; fhir:code [ fhir:v "unavailable" ] ] ) ] ; ( fhir:section [ fhir:title [ fhir:v "Package leaflet: Information for the user" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "Package leaflet: Information for the user" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>" ] ] [ fhir:title [ fhir:v "What is in this leaflet" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "What is in this leaflet" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What is in this leaflet</p><ol type=\"1\"><li>What Trizivir is and what it is used for</li><li>What you need to know before you take Trizivir</li><li>How to take Trizivir</li><li>Possible side effects</li><li>How to store Trizivir</li><li>Contents of the pack and other information</li></ol></div>" ] ] [ fhir:title [ fhir:v "1. What trizivir is and what it is used for" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "1. What trizivir is and what it is used for" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Trizivir is used to treat HIV (human immunodeficiency virus) infection in adults.</p><p>Trizivir contains three active ingredients that are used to treat HIV infection: abacavir, lamivudine and zidovudine. All of these belong to a group of anti-retroviral medicines called nucleoside analogue reverse transcriptase inhibitors (NRTIs).</p><p>Trizivir helps to control your condition. Trizivir does not cure HIV infection; it reduces the amount of virus in your body and keeps it at a low level. This helps your body to increase the CD4 cell count in your blood. CD4 cells are a type of white blood cell that are important in helping your body to fight infection.</p><p>Not everyone responds to treatment with Trizivir in the same way. Your doctor will monitor the effectiveness of your treatment.</p></div>" ] ] [ fhir:title [ fhir:v "2. What you need to know before you take trizivir" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "2. What you need to know before you take trizivir" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Do not take Trizivir:</p><ul><li>if you are allergic (hypersensitive) to abacavir (or any other medicine containing abacavir Kivexa, Triumeq or Ziagen), lamivudine or zidovudine, or any of the other ingredients of this medicine (listed in Section 6) Carefully read all the information about hypersensitivity reactions in Section 4. * if you have severe kidney problems</li><li>if you have a very low red blood cell count (anaemia) or a very low white blood cell count (neutropenia) Check with your doctor if you think any of these apply to you.</li></ul><p>Take special care with Trizivir Some people taking Trizivir are more at risk of serious side effects. You need to be aware of the extra risks:</p><ul><li>if you have moderate or severe liver disease</li><li>if you have ever had liver disease, including hepatitis B or C (if you have hepatitis B infection, do not stop Trizivir without your doctor s advice, as your hepatitis may come back)</li><li>if you are seriously overweight (especially if you are a woman) Talk to your doctor if any of these apply to you before using Trizivir. You may need extra check-ups, including blood tests, while you are taking your medicine. See Section 4 for more information.</li></ul><p>Abacavir hypersensitivity reactions Even patients who don t have the HLA-B*5701 gene may still develop a hypersensitivity reaction (a serious allergic reaction).Carefully read all the information about hypersensitivity reactions in Section 4 of this leaflet.</p><p>Risk of cardiovascular events It cannot be excluded that abacavir may increase the risk of having cardiovascular events. Tell your doctor if you have cardiovascular problems, if you smoke, or have other illnesses that may increase your risk of cardiovascular diseases such as high blood pressure, or diabetes. Do not stop taking Trizivir unless your doctor advises you to do so.</p><p>Look out for important symptoms Some people taking Trizivir develop other conditions, which can be serious. You need to know about important signs and symptoms to look out for while you are taking Trizivir. Read the information Other possible side effects of Trizivir in Section 4 of this leaflet.</p><p>Other medicines and Trizivir Tell your doctor or pharmacist if you are taking any other medicines, or if you have taken any recently, including herbal medicines or other medicines you bought without a prescription.<br/>Remember to tell your doctor or pharmacist if you begin taking a new medicine while you are taking Trizivir.</p><p>These medicines should not be used with Trizivir:</p><ul><li>stavudine or emtricitabine, to treat HIV infection</li><li>other medicinal products containing lamivudine, used to treat HIV infection or hepatitis B infection</li><li>ribavirin or injections of ganciclovir to treat viral infections</li><li>high doses of co-trimoxazole, an antibiotic</li><li>cladribine, used to treat hairy cell leukaemia Tell your doctor if you are being treated with any of these.</li></ul><p>Some medicines can make it more likely that you will have side effects, or make side effects worse<br/>These include:</p><ul><li>sodium valproate, to treat epilepsy</li><li>interferon, to treat viral infections</li><li>pyrimethamine, to treat malaria and other parasitic infections</li><li>dapsone, to prevent pneumonia and treat skin infections</li><li>fluconazole or flucytosine, to treat fungal infections such as candida</li><li>pentamidine or atovaquone, to treat parasitic infections such as Pneumocystis jirovecii pneumonia (often referred to as PCP)</li><li>amphotericin or co-trimoxazole, to treat fungal and bacterial infections</li><li>probenecid, to treat gout and similar conditions, and given with some antibiotics to make them more effective</li><li>methadone, used as a heroin substitute</li><li>vincristine, vinblastine or doxorubicin, to treat cancer Tell your doctor if you re taking any of these.</li></ul><p>Some medicines interact with Trizivir These include:</p><ul><li><p>clarithromycin, an antibiotic If you are taking clarithromycin, take your dose at least 2 hours before or after you take your Trizivir.</p></li><li><p>phenytoin, for treating epilepsy Tell your doctor if you are taking phenytoin. Your doctor may need to monitor you while you are taking Trizivir</p></li><li><p>medicines (usually liquids) containing sorbitol and other sugar alcohols (such as xylitol, mannitol, lactitol or maltitol), if taken regularly. Tell your doctor or pharmacist if you are taking any of these.</p></li><li><p>riociguat, for treating high blood pressure in the blood vessels (the pulmonary arteries) that carry blood from the heart to the lungs. Your doctor may need to reduce your riociguat dose, as abacavir may increase riociguat blood levels.</p></li></ul><p>Methadone and Trizivir Abacavir increases the rate at which methadone is removed from the body. If you are taking methadone, you will be checked for any withdrawal symptoms. Your methadone dose may need to be changed.</p><p>Pregnancy If you are pregnant, if you become pregnant or if you are planning to become pregnant, talk to your doctor about the risks and benefits to you and your baby of taking Trizivir during your pregnancy.<br/>Trizivir and similar medicines may cause side effects in unborn babies.<br/>If you have taken Trizivir during your pregnancy, your doctor may request regular blood tests and other diagnostic tests to monitor the development of your child. In children whose mothers took NRTIs during pregnancy, the benefit from the protection against HIV outweighed the risk of side effects.</p><p>Breast-feeding Breast-feeding is not recommended in women living with HIV because HIV infection can be passed on to the baby in breast milk. A small amount of the ingredients in Trizivir can also pass into your breast milk. If you are breast-feeding, or thinking about breast-feeding, you should discuss it with your doctor as soon as possible.</p><p>Driving and using machines Trizivir can make you dizzy and have other side effects that make you less alert. Don t drive or operate machines unless you re feeling well.</p><p>Important information about some of the other ingredients of Trizivir tablets. This medicine contains less than 1 mmol sodium (23 mg) per dosage unit, that is to say essentially sodium-free .</p></div>" ] ] [ fhir:title [ fhir:v "3. How to take trizivir" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "3. How to take trizivir" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. Keep in touch with your doctor, and do not stop taking Trizivir without your doctor s advice.</p><p>How much to take The usual dose of Trizivir for adults is one tablet twice a day.<br/>Take the tablets at regular times, leaving approximately 12 hours between each tablet.</p><p>Swallow the tablets whole, with some water. Trizivir can be taken with or without food.</p><p>If you take more Trizivir than you should If you accidentally take too much Trizivir, tell your doctor or your pharmacist, or contact your nearest hospital emergency department for further advice.</p><p>If you forget to take Trizivir If you forget to take a dose, take it as soon as you remember. Then continue your treatment as before.<br/>Do not take a double dose to make up for a forgotten dose.</p><p>It is important to take Trizivir regularly, because if you take it at irregular intervals it may not continue to work against the HIV infection, and you may be more likely to have a hypersensitivity reaction.</p><p>If you have stopped taking Trizivir If you have stopped taking Trizivir for any reason especially because you think you are having side effects, or because you have other illness: Talk to your doctor before you start taking it again. Your doctor will check whether your symptoms were related to a hypersensitivity reaction. If the doctor thinks they may have been related, you will be told never again to take Trizivir, or any other medicine containing abacavir (Kivexa,Triumeq or Ziagen). It is important that you follow this advice.</p><p>If your doctor advises that you can start taking Trizivir again, you may be asked to take your first doses in a place where you will have ready access to medical care if you need it.</p></div>" ] ] [ fhir:title [ fhir:v "4. Possible side effects" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "4. Possible side effects" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>During HIV therapy there may be an increase in weight and in levels of blood lipids and glucose. This is partly linked to restored health and life style, and in the case of blood lipids sometimes to the HIV medicines themselves. Your doctor will test for these changes.</p><p>Treatment with Trizivir often causes a loss of fat from legs, arms and face (lipoatrophy). This loss of body fat has been shown to be not fully reversible after discontinuation of zidovudine. Your doctor should monitor for signs of lipoatrophy. Tell your doctor if you notice any loss of fat from your legs, arms, and face. When these signs occur, Trizivir should be stopped and your HIV treatment changed.</p><p>Like all medicines, this medicine can cause side effects, although not everyone gets them.</p><p>When you are being treated for HIV, it can be hard to tell whether a symptom is a side effect of Trizivir or other medicines you are taking, or an effect of the HIV infection itself. So it is very important to talk to your doctor about any changes in your health.</p><p>Even patients who don t have the HLA-B*5701 gene may still develop a hypersensitivity reaction (a serious allergic reaction), described in this leaflet in the panel headed Hypersensitivity reactions . It is very important that you read and understand the information about this serious reaction.</p><p>As well as the side effects listed below for Trizivir, other conditions can develop during treatment.<br/>It is important to read the information on the other side of this leaflet under Other possible side effects of Trizivir .</p><p>Hypersensitivity reactions Trizivir contains abacavir (which is also an active substance in Kivexa, Triumeq and Ziagen). Abacavir can cause a serious allergic reaction known as a hypersensitivity reaction. These hypersensitivity reactions have been seen more frequently in people taking medicines that contain abacavir.<br/>Who gets these reactions? Anyone taking Trizivir could develop a hypersensitivity reaction to abacavir, which could be life threatening if they continue to take Trizivir. You are more likely to develop such a reaction if you have a gene called HLA-B*5701 (but you can get a reaction even if you do not have this gene). You should have been tested for this gene before Trizivir was prescribed for you. If you know you have this gene, tell your doctor before you take Trizivir.</p><p>About 3 to 4 in every 100 patients treated with abacavir in a clinical trial who did not have the HLA- B*5701 gene developed a hypersensitivity reaction.</p><p>What are the symptoms? The most common symptoms are:</p><ul><li>fever (high temperature) and skin rash Other common symptoms are:</li><li>nausea (feeling sick), vomiting (being sick), diarrhoea, abdominal (stomach) pain, severe tiredness Other symptoms include: Pains in the joints or muscles, swelling of the neck, shortness of breath, sore throat, cough, occasional headaches, inflammation of the eye (conjunctivitis), mouth ulcers, low blood pressure, tingling or numbness of the hands or feet.</li></ul><p>When do these reactions happen? Hypersensitivity reactions can start at any time during treatment with Trizivir, but are more likely during the first 6 weeks of treatment.</p><p>Contact your doctor immediately: 1 if you get a skin rash, OR 2 if you get symptoms from at least 2 of the following groups:</p><ul><li><p>fever</p></li><li><p>shortness of breath, sore throat or cough</p></li><li><p>nausea or vomiting, diarrhoea or abdominal pain</p></li><li><p>severe tiredness or achiness, or generally feeling ill</p></li></ul><p>Your doctor may advise you to stop taking Trizivir.</p><p>If you have stopped taking Trizivir If you have stopped taking Trizivir because of a hypersensitivity reaction, you must NEVER AGAIN take Trizivir, or any other medicine containing abacavir (Kivexa, Triumeq or Ziagen). If you do, within hours, your blood pressure could fall dangerously low, which could result in death.</p><p>If you have stopped taking Trizivir for any reason especially because you think you are having side effects, or because you have other illness: Talk to your doctor before you start again. Your doctor will check whether your symptoms were related to a hypersensitivity reaction. If the doctor thinks they may have been, you will then be told never again to take Trizivir, or any other medicine containing abacavir (Kivexa, Triumeq or Ziagen). It is important that you follow this advice.</p><p>Occasionally, hypersensitivity reactions have developed in people who start taking abacavir containing products again, but who had only one symptom on the Alert Card before they stopped taking it.</p><p>Very rarely, patients who have taken medicines containing abacavir in the past without any symptoms of hypersensitivity have developed a hypersensitivity reaction when they start taking these medicines again.</p><p>If your doctor advises that you can start taking Trizivir again, you may be asked to take your first doses in a place where you will have ready access to medical care if you need it.</p><p>If you are hypersensitive to Trizivir, return all your unused Trizivir tablets for safe disposal. Ask your doctor or pharmacist for advice. The Trizivir pack includes an Alert Card, to remind you and medical staff about hypersensitivity reactions. Detach this card and keep it with you at all times.</p><p>Very common side effects These may affect more than 1 in 10 people:</p><ul><li>headache</li><li>feeling sick (nausea)</li></ul><p>Common side effects These may affect up to 1 in 10 people:</p><ul><li><p>hypersensitivity reaction</p></li><li><p>being sick (vomiting)</p></li><li><p>diarrhoea</p></li><li><p>stomach pains</p></li><li><p>loss of appetite</p></li><li><p>feeling dizzy</p></li><li><p>tiredness, lack of energy</p></li><li><p>fever (high temperature)</p></li><li><p>general feeling of being unwell</p></li><li><p>difficulty in sleeping (insomnia)</p></li><li><p>muscle pain and discomfort</p></li><li><p>joint pain</p></li><li><p>cough</p></li><li><p>irritated or runny nose</p></li><li><p>skin rash</p></li><li><p>hair loss Common side effects that may show up in blood tests are:</p></li><li><p>a low red blood cell count (anaemia) or low white blood cell count (neutropenia or leukopenia)</p></li><li><p>an increase in the level of liver enzymes</p></li><li><p>an increased amount in the blood of bilirubin (a substance produced in the liver) which may make your skin appear yellow</p></li></ul><p>Uncommon side effects These may affect up to 1 in 100 people:</p><ul><li>feeling breathless</li><li>wind (flatulence)</li><li>itching</li><li>muscle weakness An uncommon side effect that may show up in blood tests is:</li><li>a decrease in the number of cells involved in blood clotting (thrombocytopenia), or in all kinds of blood cells (pancytopenia)</li></ul><p>Rare side effects These may affect up to 1 in 1000 people:</p><ul><li>liver disorders, such as jaundice, enlarged liver or fatty liver, inflammation (hepatitis)</li><li>lactic acidosis (excess lactic acid in the blood ; see the next section, Other possible side effects of Trizivir )</li><li>inflammation of the pancreas (pancreatitis)</li><li>chest pain; disease of the heart muscle (cardiomyopathy)</li><li>fits (convulsions)</li><li>feeling depressed or anxious, not being able to concentrate, feeling drowsy</li><li>indigestion, taste disturbance</li><li>changes in the colour of your nails, your skin, or the skin inside your mouth</li><li>a flu-like feeling chills and sweating</li><li>tingly feelings in the skin (pins and needles)</li><li>sensation of weakness in the limbs</li><li>breakdown of muscle tissue</li><li>numbness</li><li>passing urine more often</li><li>enlarged breasts in men Rare side effects that may show up in blood tests are:</li><li>increase in an enzyme called amylase</li><li>a failure of the bone marrow to produce new red blood cells (pure red cell aplasia)</li></ul><p>Very rare side effects These may affect up to 1 in 10,000 people:</p><ul><li>skin rash, which may form blisters and looks like small targets (central dark spots surrounded by a paler area, with a dark ring around the edge) (erythema multiforme)</li><li>a widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals (Stevens Johnson syndrome), and a more severe form causing skin peeling in more than 30% of the body surface (toxic epidermal necrolysis) If you notice any of these symptoms contact a doctor urgently. A very rare side effect that may show up in blood tests is:</li></ul><p>a failure of the bone marrow to produce new red or white blood cells (aplastic anaemia)</p><p>If you get side effects</p><p>Tell your doctor or pharmacist if any of the side effects gets severe or troublesome, or if you notice any side effects not listed in this leaflet.</p><p>Other possible side effects of Trizivir Trizivir may cause other conditions to develop during HIV treatment.</p><p>Symptoms of infection and inflammation</p><p>Old infections may flare up People with advanced HIV infection (AIDS) have weak immune systems, and are more likely to develop serious infections (opportunistic infections). When these people start treatment, they may find that old, hidden infections flare up, causing signs and symptoms of inflammation. These symptoms are probably caused by the body s immune system becoming stronger, so that the body starts to fight these infections. Symptoms usually include fever, plus some of the following:</p><ul><li>headache</li><li>stomach ache</li><li>difficulty breathing</li></ul><p>In rare cases, as the immune system becomes stronger, it can also attack healthy body tissue (autoimmune disorders). The symptoms of autoimmune disorders may develop many months after you start taking medicine to treat your HIV infection. Symptoms may include:</p><ul><li>palpitations (rapid or irregular heartbeat) or tremor</li><li>hyperactivity (excessive restlessness and movement)</li><li>weakness beginning in the hands and feet and moving up towards the trunk of the body</li></ul><p>If you get any symptoms of infection while you re taking Trizivir: Tell your doctor immediately. Do not take other medicines for the infection without your doctor s advice.</p><p>Lactic acidosis is a rare but serious side effect Some people taking Trizivir develop a condition called lactic acidosis, together with an enlarged liver.</p><p>Lactic acidosis is caused by a build-up of lactic acid in the body. It is rare; if it happens, it usually develops after a few months of treatment. It can be life-threatening, causing failure of internal organs.</p><p>Lactic acidosis is more likely to develop in people who have liver disease, or in obese (very overweight) people, especially women. Signs of lactic acidosis include:</p><ul><li>feeling sick (nausea), being sick (vomiting)</li><li>stomach pain</li><li>generally feeling unwell</li><li>loss of appetite, weight loss</li><li>deep, rapid, difficult breathing</li><li>numbness or weakness in the limbs During your treatment, your doctor will monitor you for signs of lactic acidosis. If you have any of the symptoms listed above or any other symptoms that worry you: See your doctor as soon as possible.</li></ul><p>You may have problems with your bones Some people taking combination therapy for HIV develop a condition called osteonecrosis. With this condition, parts of the bone tissue die because of reduced blood supply to the bone. People may be more likely to get this condition:</p><ul><li>if they have been taking combination therapy for a long time</li><li>if they are also taking anti-inflammatory medicines called corticosteroids</li><li>if they drink alcohol</li><li>if their immune systems are very weak</li><li>if they are overweight Signs of osteonecrosis include:</li><li>stiffness in the joints</li><li>aches and pains (especially in the hip, knee or shoulder)</li><li>difficulty moving If you notice any of these symptoms: Tell your doctor.</li></ul><p>Other effects may show up in blood tests Trizivir can also cause:</p><ul><li>increased levels of lactic acid in the blood, which on rare occasions can lead to lactic acidosis</li></ul><p>Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>" ] ] [ fhir:title [ fhir:v "5. How to store trizivir" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "5. How to store trizivir" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Keep this medicine out of the sight and reach of children.</p><p>Do not take this medicine after the expiry date shown on the carton. The expiry date refers to the last day of that month.</p><p>Do not store above 30 C.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures help protect the environment.</p></div>" ] ] [ fhir:title [ fhir:v "6. Contents of the pack and other information" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "6. Contents of the pack and other information" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What Trizivir contains The active substances in each Trizivir film-coated tablet are 300 mg of abacavir (as sulfate), 150 mg lamivudine and 300 mg zidovudine.</p><p>The other ingredients are microcrystalline cellulose, sodium starch glycollate and magnesium stearate in the core of the tablet. The tablet coating contains hypromellose, titanium dioxide, polyethylene glycol, indigo carmine aluminium lake, iron oxide yellow.</p><p>What Trizivir looks like and contents of the pack Trizivir film-coated tablets are engraved with GX LL1 on one side. They are blue/green and capsule- shaped and are provided in blister packs containing 60 tablets or bottles containing 60 tablets with child-resistant tops.</p><p>Marketing Authorisation Holder ViiV Healthcare BV Van Asch van Wijckstraat 55H</p><p>3811 LP Amersfoort Netherlands</p><p>Manufacturer Delpharm Pozna Sp ka Akcyjna, ul. Grunwaldzka 189 , 60-322 Poznan, Poland</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:</p><p>Belgi /Belgique/Belgien ViiV Healthcare srl/bv</p><p>T l/Tel: + 32 (0) 10 85 65 Lietuva ViiV Healthcare BV Tel: + 370 80000<br/>ViiV Healthcare BV Te .: + 359 80018Luxembourg/Luxemburg ViiV Healthcare srl/bv</p><p>Belgique/Belgien T l/Tel: + 32 (0) 10 85 65 esk republika GlaxoSmithKline s.r.o. Tel: + 420 222 001 <a href=\"mailto:cz.info@gsk.com\">cz.info@gsk.com</a></p><p>Magyarorsz g ViiV Healthcare BV Tel.: + 36 80088Danmark GlaxoSmithKline Pharma A/S Tlf: + 45 36 35 91 <a href=\"mailto:dk-info@gsk.com\">dk-info@gsk.com</a></p><p>Malta ViiV Healthcare BV Tel: + 356 80065Deutschland ViiV Healthcare GmbH<br/>Tel.: + 49 (0)89 203 <a href=\"mailto:0038-viiv.med.info@viivhealthcare.com\">0038-viiv.med.info@viivhealthcare.com</a></p><p>Nederland ViiV Healthcare BV<br/>Tel: + 31 (0) 33 2081Eesti ViiV Healthcare BV Tel: + 372 8002Norge GlaxoSmithKline AS Tlf: + 47 22 70 20<br/>GlaxoSmithKline A.E.B.E. : + 30 210 68 82 sterreich GlaxoSmithKline Pharma GmbH Tel: + 43 (0)1 97075 0 <a href=\"mailto:at.info@gsk.com\">at.info@gsk.com</a></p><p>Espa a Laboratorios ViiV Healthcare, S.L.<br/>Tel: +34 900 923 <a href=\"mailto:es-ci@viivhealthcare.com\">es-ci@viivhealthcare.com</a></p><p>Polska GSK Services Sp. z o.o. Tel.: + 48 (0)22 576 9France ViiV Healthcare SAS<br/>T l.: + 33 (0)1 39 17 <a href=\"mailto:6Infomed@viivhealthcare.com\">6Infomed@viivhealthcare.com</a></p><p>Hrvatska ViiV Healthcare BV Tel: + 385 800787Portugal VIIVHIV HEALTHCARE, UNIPESSOAL, LDA<br/>Tel: + 351 21 094 08 <a href=\"mailto:viiv.fi.pt@viivhealthcare.com\">viiv.fi.pt@viivhealthcare.com</a></p><p>Rom nia ViiV Healthcare BV<br/>Tel: + 40800672Ireland GlaxoSmithKline (Ireland) Limited Tel: + 353 (0)1 4955Slovenija ViiV Healthcare BV Tel: + 386 80688 sland Vistor hf.<br/>S mi: +354 535 7Slovensk republika ViiV Healthcare BV Tel: + 421 800500Italia ViiV Healthcare S.r.l<br/>Tel: + 39 (0)45 7741Suomi/Finland GlaxoSmithKline Oy Puh/Tel: + 358 (0)10 30 30<br/>ViiV Healthcare BV : + 357 80070Sverige GlaxoSmithKline AB Tel: + 46 (0)8 638 93 <a href=\"mailto:info.produkt@gsk.com\">info.produkt@gsk.com</a></p><p>Latvija ViiV Healthcare BV Tel: + 371 80205United Kingdom (Northern Ireland) ViiV Healthcare BV<br/>Tel: + 44 (0)800 <a href=\"mailto:221customercontactuk@gsk.com\">221customercontactuk@gsk.com</a></p><p>This leaflet was last revised in {MM/YYYY}</p><p>Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>" ] ] ) ] ) . # <MedicinalProductDefinition/mp2dca39e00c4bb300a2d0bc7e52b63f20> a fhir:MedicinalProductDefinition ; fhir:id [ fhir:v "mp2dca39e00c4bb300a2d0bc7e52b63f20"] ; # fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"^^xsd:anyURI ; fhir:link <http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi> ] ) ] ; # fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><a name=\"MedicinalProductDefinition_mp2dca39e00c4bb300a2d0bc7e52b63f20\"> </a><p class=\"res-header-id\"><b>Generated Narrative: MedicinalProductDefinition mp2dca39e00c4bb300a2d0bc7e52b63f20</b></p><a name=\"mp2dca39e00c4bb300a2d0bc7e52b63f20\"> </a><a name=\"hcmp2dca39e00c4bb300a2d0bc7e52b63f20\"> </a><a name=\"mp2dca39e00c4bb300a2d0bc7e52b63f20-en-US\"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/00/156/002 – opaque white PCTFE/PVC-Al Blister pack (60 Tablets)</p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}\">Medicinal Product</span></p><p><b>domain</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-domain Human}\">Human use</span></p><p><b>status</b>: <span title=\"Codes:{http://hl7.org/fhir/publication-status active}\">active</span></p><p><b>legalStatusOfSupply</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi 100000072084}\">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: TRIZIVIR 300 mg/150 mg/300 mg film-coated tablets</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}\">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}\">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}\">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}\">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}\">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:ietf:bcp:47 en}\">en</span></td></tr></table></blockquote></div>" ] ; # fhir:identifier ( [ fhir:system [ fhir:v "http://ema.europa.eu/identifier"^^xsd:anyURI ] ; fhir:value [ fhir:v "EU/1/00/156/002 – opaque white PCTFE/PVC-Al Blister pack (60 Tablets)" ] ] ) ; # fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/medicinal-product-type"^^xsd:anyURI ] ; fhir:code [ fhir:v "MedicinalProduct" ] ; fhir:display [ fhir:v "Medicinal Product" ] ] ) ] ; # fhir:domain [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/medicinal-product-domain"^^xsd:anyURI ] ; fhir:code [ fhir:v "Human" ] ; fhir:display [ fhir:v "Human use" ] ] ) ] ; # fhir:status [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/publication-status"^^xsd:anyURI ] ; fhir:code [ fhir:v "active" ] ; fhir:display [ fhir:v "active" ] ] ) ] ; # fhir:legalStatusOfSupply [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000072084" ] ; fhir:display [ fhir:v "Medicinal product subject to medical prescription" ] ] ) ] ; # fhir:name ( [ fhir:productName [ fhir:v "TRIZIVIR 300 mg/150 mg/300 mg film-coated tablets" ] ; fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/lists/220000000000"^^xsd:anyURI ] ; fhir:code [ fhir:v "220000000001" ] ; fhir:display [ fhir:v "Full name" ] ] ) ] ; ( fhir:part [ fhir:part [ fhir:v "nan" ] ; fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/lists/220000000000"^^xsd:anyURI ] ; fhir:code [ fhir:v "220000000002" ] ; fhir:display [ fhir:v "Invented name part" ] ] ) ] ] [ fhir:part [ fhir:v "nan" ] ; fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/lists/220000000000"^^xsd:anyURI ] ; fhir:code [ fhir:v "220000000003" ] ; fhir:display [ fhir:v "Scientific name part" ] ] ) ] ] [ fhir:part [ fhir:v "nan" ] ; fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/lists/220000000000"^^xsd:anyURI ] ; fhir:code [ fhir:v "220000000004" ] ; fhir:display [ fhir:v "Strength part" ] ] ) ] ] [ fhir:part [ fhir:v "nan" ] ; fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/lists/220000000000"^^xsd:anyURI ] ; fhir:code [ fhir:v "220000000005" ] ; fhir:display [ fhir:v "Pharmaceutical dose form part" ] ] ) ] ] ) ; ( fhir:usage [ fhir:country [ ( fhir:coding [ fhir:system [ fhir:v "urn:iso:std:iso:3166"^^xsd:anyURI ] ; fhir:code [ fhir:v "EU" ] ; fhir:display [ fhir:v "EU" ] ] ) ] ; fhir:jurisdiction [ ( fhir:coding [ fhir:system [ fhir:v "urn:iso:std:iso:3166"^^xsd:anyURI ] ; fhir:code [ fhir:v "EU" ] ; fhir:display [ fhir:v "EU" ] ] ) ] ; fhir:language [ ( fhir:coding [ fhir:system [ fhir:v "urn:ietf:bcp:47"^^xsd:anyURI ] ; fhir:code [ fhir:v "en" ] ; fhir:display [ fhir:v "en" ] ] ) ] ] ) ] ) . #
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
